Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.

doi:10.1002/ctm2.304

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.

Clinical and translational medicine - 1 Feb 2021

Quijada-Álamo Miguel, Pérez-Carretero Claudia, Hernández-Sánchez María, Rodríguez-Vicente Ana-Eugenia, Herrero Ana-Belén, Hernández-Sánchez Jesús-María, Martín-Izquierdo Marta, Santos-Mínguez Sandra, Del Rey Mónica, González Teresa, Rubio-Martínez Araceli, García de Coca Alfonso, Dávila-Valls Julio, Hernández-Rivas José-Ángel, Parker Helen, Strefford Jonathan C, Benito Rocío, Ordóñez José-Luis, Hernández-Rivas Jesús-María

Abstract excerpt

BACKGROUND: Several genetic alterations have been identified as driver events in chronic lymphocytic leukemia (CLL) pathogenesis and oncogenic evolution. Concurrent driver alterations usually coexist within the same tumoral clone, but how the cooperation of multiple genomic abnormalities contributes to disease progression remains poorly understood. Specifically, the biological and clinical consequences of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Deletion

Share to Disease Models, Animal

Share to Disease Progression

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 33634999
DOI: 10.1002/ctm2.304
PMCID: PMC7862176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.PMID 33634999Read ↗

CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.Semantic proximity Read ↗

Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemiaSemantic proximity Read ↗

Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosisSemantic proximity Read ↗

The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.Semantic proximity Read ↗

The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Semantic proximity Read ↗

Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Therapy-driven clonal dynamics in chronic lymphocytic leukemia.Semantic proximity Read ↗

Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.Semantic proximity Read ↗

Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.Semantic proximity Read ↗

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.Semantic proximity Read ↗

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.